DLX6-AS1

Summary

DLX6-AS1 (DLX6 antisense RNA 1, HGNC:37151) is a long non-coding RNA gene on chromosome 7q21.3.

Predicted to be involved in forebrain development and positive regulation of DNA-templated transcription. Predicted to act upstream of or within positive regulation of transcription by RNA polymerase II. Predicted to be located in nucleus.

Source: NCBI Gene 285987 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37151
Approved symbol	DLX6-AS1
Name	DLX6 antisense RNA 1
Location	7q21.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	uc.221, uc.220, FLJ34048, Evf-2
Ensembl gene	ENSG00000231764
Ensembl biotype	lncRNA
Entrez	285987
RNAcentral	URS0000759F04 — lncRNA, 1990 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 38 lncRNA

ENST00000430027, ENST00000430404, ENST00000437331, ENST00000437541, ENST00000452769, ENST00000458352, ENST00000605417, ENST00000654988, ENST00000656954, ENST00000658043, ENST00000659765, ENST00000685183, ENST00000688080, ENST00000841643, ENST00000841658, ENST00000841661, ENST00000841663, ENST00000841665, ENST00000841667, ENST00000841669, ENST00000841671, ENST00000841673, ENST00000841675, ENST00000841677, ENST00000841679, ENST00000841681, ENST00000841683, ENST00000841685, ENST00000841687, ENST00000841689, ENST00000841692, ENST00000841694, ENST00000841695, ENST00000841697, ENST00000841699, ENST00000841701, ENST00000841703, ENST00000841705

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000430027 — 3 exons

Exon	Start	End
ENSE00001739625	96978347	96979591
ENSE00001742177	97013925	97014065
ENSE00001764165	96955141	96969118

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 92.27.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0417 / max 821.4496, expressed in 186 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
85015	1.4988	143
85008	0.5164	95
85014	0.4871	107
85013	0.2650	39
85016	0.1369	36
85007	0.0614	30
85009	0.0399	20
85017	0.0363	11

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	92.27	gold quality
ventricular zone	UBERON:0003053	84.76	gold quality
cortical plate	UBERON:0005343	81.27	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.81	gold quality
prefrontal cortex	UBERON:0000451	76.24	gold quality
anterior cingulate cortex	UBERON:0009835	75.91	gold quality
endometrium	UBERON:0001295	74.52	gold quality
caudate nucleus	UBERON:0001873	73.42	gold quality
calcaneal tendon	UBERON:0003701	72.70	gold quality
nucleus accumbens	UBERON:0001882	72.62	gold quality
neocortex	UBERON:0001950	72.60	gold quality
frontal cortex	UBERON:0001870	71.60	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	71.28	gold quality
tibia	UBERON:0000979	70.99	gold quality
putamen	UBERON:0001874	70.91	gold quality
right frontal lobe	UBERON:0002810	70.70	gold quality
colonic epithelium	UBERON:0000397	70.67	silver quality
amygdala	UBERON:0001876	70.29	gold quality
cerebral cortex	UBERON:0000956	69.70	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.57	gold quality
forebrain	UBERON:0001890	67.81	gold quality
placenta	UBERON:0001987	66.44	gold quality
brain	UBERON:0000955	66.31	gold quality
hindlimb stylopod muscle	UBERON:0004252	66.21	gold quality
temporal lobe	UBERON:0001871	65.92	gold quality
Brodmann (1909) area 46	UBERON:0006483	65.79	gold quality
hypothalamus	UBERON:0001898	64.20	gold quality
primary visual cortex	UBERON:0002436	64.18	gold quality
uterus	UBERON:0000995	63.77	gold quality
superior frontal gyrus	UBERON:0002661	62.36	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	639.43
E-HCAD-35	yes	569.30
E-HCAD-25	yes	52.29
E-ANND-3	yes	7.48

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 27)

• finding supports that DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1, acting as a novel therapeutic target for glioma. (PMID:30366080)
• DLX6-AS1, combined with miR-129-5p and DLK1, can be utilized as factors for the clinical diagnosis and prognosis of osteosarcoma. (PMID:30442366)
• Knockdown of DLX6AS1 significantly suppressed cell proliferation, invasion and migration abilities, and enhanced the apoptotic rate in the two esophageal squamous cell carcinoma (ESCC) cell lines. Furthermore, western blot assays revealed that silencing DLX6AS1 partly influenced the epithelialmesenchymal transition process in ESCC cells. (PMID:30592268)
• DLX6-AS1 is highly expressed in esophageal squamous cell carcinoma tissue and cells and indicates poor prognosis. DLX6-AS1 promotes proliferation and inhibits apoptosis of esophageal cancer cells by upregulating the expression of the mTOR gene. (PMID:30802540)
• Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p. (PMID:30805988)
• Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway. (PMID:31081076)
• DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer. (PMID:31463827)
• DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1. (PMID:31591939)
• Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis. (PMID:31615303)
• We identified the oncogenic role of DLX6-AS1 in the carcinogenesis of breast cancer, and the elevated expression of DLX6-AS1 was associated with malignant progression of breast cancer. (PMID:31705901)
• LncRNA DLX6-AS1 increases the expression of HIF-1alpha and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p. (PMID:31782911)
• Long Noncoding RNA DLX6-AS1 Promotes the Progression in Cervical Cancer by Targeting miR-16-5p/ARPP19 Axis. (PMID:32077747)
• The regulatory network of lncRNA DLX6-AS1/miR-149-5p/ERP44 is possibly related to the progression of preeclampsia. (PMID:32250737)
• Knockdown of LncRNA DLX6-AS1 inhibits HK-2 cell pyroptosis via regulating miR-223-3p/NLRP3 pathway in lipopolysaccharide-induced acute kidney injury. (PMID:32666494)
• Long non-coding RNA DLX6-AS1 facilitates bladder cancer progression through modulating miR-195-5p/VEGFA signaling pathway. (PMID:32756011)
• Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region. (PMID:32951317)
• Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis. (PMID:33031637)
• DLX6-AS1 accelerates cell proliferation through regulating miR-497-5p/SNCG pathway in prostate cancer. (PMID:33035382)
• Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. (PMID:33277615)
• Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer. (PMID:33550924)
• DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression. (PMID:33607068)
• Silencing long non-coding RNA DLX6-AS1 or restoring microRNA-193b-3p enhances thyroid carcinoma cell autophagy and apoptosis via depressing HOXA1. (PMID:34514705)
• DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis. (PMID:34697393)
• DLX6-AS1: a putative lncRNA candidate in multiple human cancers. (PMID:34823630)
• cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1. (PMID:35093327)
• A Peptide Encoded by a Long Non-Coding RNA DLX6-AS1 Facilitates Cell Proliferation, Migration, and Invasion by Activating the wnt/beta-Catenin Signaling Pathway in Non-Small-Cell Lung Cancer Cell. (PMID:36017915)
• Expression of lncRNA DLX6-AS1 in patients with hepatic carcinoma and its prognostic value. (PMID:37078565)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.